Magnolol was evaluated using MTT cell viability assays in CT26 and A431 cells. The reported IC50 in CT26 and HT29 cells was around 75 μM at 24 h. In A431 cells treated with Magnolol, viability relative to controls ranged from 80 - 50% at 48 h. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Magnolol and Cell Viability in Colon Cancer Cells
Cell-based study · CT26 [1]
CT26 cells were treated with Magnolol and evaluated using an MTT cell viability assay. The reported IC50 in CT26 and HT29 cells was around 75 μM at 24 h.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 25, 50, 75, 100 μM
- Exposure duration
- 24 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Magnolol
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.2. Magnolol Suppressed Tumor Cell Growth, PKC/NF-κB Signaling, Expression of NF-κB Mediated Downstream Proteins in CRC Cells (S11); 4. Materials and Methods > 4.3. Cell Viability (MTT Assay) (S62, S63); Figure 2 legend (S128)
Cell Viability (MTT Assay): Cell Viability (MTT Assay); comparator: 0 μM magnolol — 2. Results > 2.2. Magnolol Suppressed Tumor Cell Growth, PKC/NF-κB Signaling, Expression of NF-κB Mediated Downstream Proteins in CRC Cells (S11); 4. Materials and Methods > 4.3. Cell Viability (MTT Assay) (S62)
Magnolol and Cell Viability in Epidermoid Carcinoma Cells
Cell-based study · A431 cells (9000 cells/well) [2]
A431 cells were treated with Magnolol at 75, 100, 125 μM and evaluated using an MTT assay. Cell viability relative to controls ranged from 80 - 50% at 48 h.
Literature-Reported Treatment Conditions
- Treatment concentration
- 75, 100, 125 μM
- Exposure duration
- 48 h
- Method
- this stock solution was diluted in DMEM at different concentrations and was immediately used
- Vehicle
- 0.4% DMSO
Methods and source locations
Compound reported in the paper: Magnolol
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Cell culture (S10); Methods > MTT assay for cell viability (S30, S31, S32); Results > Magnolol treatment decreased cell viability in A431 cells (S97)
Cell viability was determined at the end of each treatment by using MTT assay: Cell viability was determined at the end of each treatment by using MTT assay; comparator: growth medium 0.4% DMSO — Methods > MTT assay for cell viability (S32); Results > Magnolol treatment decreased cell viability in A431 cells (S97)